Work

From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy

Year: 2026

Type: editorial

Abstract: From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapyThe approval of donanemab and lecanemab in the European Union came with a narrower label than the pivotal trials that supported it.Both agents are restricted to patients with early symptomatic Alzheimer's disease (AD) who are apolipoprotein E (APOE) ε4 non-carriers or het-

Source: The Journal of Prevention of Alzheimer s Disease

DOI: 10.1016/j.tjpad.2026.100665

Author: Timo Grimmer

Institutions: TUM Klinikum, Technical University of Munich

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,060

OpenAlex ID: W7208745857

Cites: 3

Cited by:

Related to: